Notice of Intent to Sole Source a Blanket Purchase Agreement (BPA) for a variety of radiopharmaceuticals (radiology medications) for use in the Nuclear Medicine Division at Naval Medical Center San Diego
ID: HT941024N0136Type: Special Notice
Overview

Buyer

DEPT OF DEFENSEDEFENSE HEALTH AGENCY (DHA)DEFENSE HEALTH AGENCYFALLS CHURCH, VA, 22042, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/ab197db932f64d57bf684a787aac8f8b/view
Timeline
    Description

    The Department of Defense, through the Defense Health Agency (DHA), intends to award a sole source Blanket Purchase Agreement (BPA) to RLS (USA), Inc. for the procurement of various radiopharmaceuticals required by the Nuclear Medicine Division at Naval Medical Center San Diego (NMCSD). This five-year contract will cover the supply of 31 essential radiopharmaceuticals, four additional medications, and expedited delivery services, all of which are critical for diagnostic imaging and treatment in Nuclear Medicine. Due to the radioactive nature and short shelf-life of these medications, strict adherence to transportation regulations is necessary, with deliveries occurring daily. Interested vendors may submit capability statements by September 10, 2024, to Jennifer Collins at jennifer.e.collins23.civ@health.mil, as this opportunity does not involve competitive proposals.

    Files
    Title
    Posted
    HT941024N0136 NOI.pdf
    The Notice of Intent to Sole Source HT941024N0136 outlines the Defense Health Agency's (DHA) plan to award a five-year Blanket Purchase Agreement (BPA) to RLS (USA), Inc. for the procurement of various radiopharmaceuticals needed at Naval Medical Center San Diego (NMCSD). This sole source award is justified under the Federal Acquisition Regulation's provisions, as RLS is deemed the only provider capable of fulfilling the specific requirements for 31 essential radiopharmaceuticals, four additional medications, and expedited delivery services. Radiopharmaceuticals are crucial for diagnostic imaging and treatments in Nuclear Medicine, warranting strict adherence to transportation regulations due to their radioactive properties and short shelf-life. The BPA is set to be effective from October 1, 2024, to September 30, 2029. Interested parties may submit capability statements by the specified deadline; however, initial competitive proposals are not solicited, as the decision to proceed with a sole source contract rests solely with the government. The document emphasizes the serious nature of the contract and the limited timeframe for vendors to present their qualifications, reflecting standard government RFP practices focused on efficiency and compliance within sensitive health sectors.
    Similar Opportunities
    6505--ILLUCCIX PSMA VASD
    Veterans Affairs, Department Of
    The Department of Veterans Affairs (VA), through the Network Contracting Office (NCO) 22, intends to award a sole source firm-fixed price contract to Cardinal Health 414, LLC for the procurement of Illuccix PSMA radioactive therapy injections. This procurement is justified under FAR 8.405-6(a)(1)(B), as only one source can provide the unique supplies necessary for treating prostate cancer patients undergoing Positron Emission Tomography (PET) imaging. The Illuccix PSMA injection is FDA approved for patients with prostate cancer, particularly for those whose cancer may have metastasized or recurred, making it a critical component in their treatment. Interested parties must submit a tailored capability statement and relevant company information by 10:00 AM PT on January 21, 2025, to Hestia.Sim@va.gov, as the VA reserves the right to proceed with Cardinal Health if no adequate responses are received.
    Bicalutamide 50MG tablets
    Dept Of Defense
    The Defense Logistics Agency (DLA) is issuing a solicitation for a national requirements contract for Bicalutamide 50MG tablets, available in bottle counts of 30 and 500. The procurement aims to establish a reliable supply source for these pharmaceutical items, which are critical for various Department of Defense and other federal health programs, including the Department of Veterans Affairs and the Indian Health Service. This unrestricted and fully competitive acquisition will be a firm-fixed price contract with a one-year base and four one-year options, with proposals due by January 24, 2025. Interested parties can reach out to Keith Ryales at keith.ryales@dla.mil or 215-737-9199 for further inquiries and are encouraged to monitor the DLA Bid Board System and SAM.gov for updates on the solicitation.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense (DoD) is seeking quotations for a Blanket Purchase Agreement (BPA) and Additional Discount Program (ADP) related to the procurement of pharmaceutical agents as part of its Uniform Formulary (UF) initiative. This procurement aims to establish an effective pharmacy benefits program for the Military Health System (MHS), focusing on the clinical and cost-effectiveness of newly approved drugs across various therapeutic classes, including neurological agents, antibiotics, oncological agents, and more. The selected pharmaceutical agents will be evaluated by the Pharmacy and Therapeutics (P&T) Committee during meetings scheduled for February 5-6, 2025, with quotes due by January 16, 2025. Interested manufacturers should submit their quotes and any required documentation to the designated contacts, Tracy Banks and Patricia Tyson, at the provided email addresses.
    BPA - X-RAY FILM AND SUPPLIES PSC 6525
    Dept Of Defense
    The Department of Defense, through the Naval Surface Warfare Center Indian Head Division (NSWC IHD), is seeking to establish Blanket Purchase Agreements (BPAs) for X-ray film and supplies, specifically under the PSC code 6525 and NAICS code 325992. The procurement includes items such as radiographic film and processing chemicals, with a focus on standard commercial supplies and services offered at competitive prices. These supplies are critical for medical, dental, and veterinary imaging applications, ensuring the availability of essential materials for various imaging needs. Interested vendors must submit their documentation and past performance references to Barbara Grinder by April 30 for June awards or by October 31 for December awards, with evaluations based on past performance and customer satisfaction. For further inquiries, vendors can contact Barbara Grinder at barbara.j.grinder.civ@us.navy.mil or Brandi L. Sorzano at brandi.l.sorzano.civ@us.navy.mil.
    Rabeprazole Sodium Delayed Release Tablets
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rabeprazole Sodium Delayed Release Tablets. The tablets will be used for medical purposes and will be available in 30, 90, and 500 count bottles. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source to provide the tablets for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. Interested parties should contact Phyllis Daraio for more information. The projected solicitation date is February 2020.
    Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program
    Dept Of Defense
    The Department of Defense, through the Defense Health Agency, is soliciting quotes for the Pharmacy Uniform Formulary Blanket Purchase Agreement and the Uniform Formulary Additional Discount Program, aimed at establishing an effective pharmacy benefits program for the Military Health System. This procurement involves the evaluation and selection of pharmaceutical agents based on their clinical and cost-effectiveness, with a focus on newly approved drugs that will be reviewed by the Pharmacy and Therapeutics Committee in February 2025. Interested vendors must submit their pricing information, including National Drug Codes (NDCs), by December 19, 2024, and are encouraged to participate in a pre-quotation teleconference on December 4, 2024. For further inquiries, vendors can contact Tracy Banks at tracy.e.banks2.civ@mail.mil or Julia Trang at julia.n.trang.civ@health.mil.
    Valsartan
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Valsartan, a drug used to treat high blood pressure and heart failure. The contract will include Valsartan tablets in various strengths and quantities. It will be a firm-fixed price, requirements type contract with a one year base and four one year options. The contract aims to establish a national supply source for Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The solicitation will be posted on the DLA Bid Board System and beta.SAM.gov, with a projected solicitation date in June 2021. Interested parties should contact Christopher Newman for more information.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.
    Notice of Intent - Sole Source Maintenance to Medtronic USA Inc
    Dept Of Defense
    The Defense Health Agency (DHA) intends to award a sole source firm fixed price contract to Medtronic USA Inc. for maintenance and support of the Medtronic StealthStation™ S8 surgical navigation system at Walter Reed National Military Medical Center (WRNMMC). This procurement is necessary to ensure the operational accuracy of the surgical navigation system, which is crucial for tracking surgical instruments during procedures. Interested parties are invited to express their capabilities by emailing the designated contacts by 10:00 AM EST on January 17th, with all submissions required to demonstrate qualifications at no cost to the government. This notice is not a request for competitive proposals, and the government retains discretion over the procurement process based on the responses received.
    Rizatriptan Benzoate
    Dept Of Defense
    Presolicitation DEPT OF DEFENSE is planning to issue a national requirements contract for Rizatriptan Benzoate tablets. The contract will establish a national supply source to provide the items listed in the schedule for purchase by Department of Defense, Department of Veterans Affairs, Indian Health Service, and Bureau of Prisons customers. The contract will be a firm-fixed price, requirements type contract with a one year base and four one year options. The solicitation will be posted on the DLA Bid Board System and SAM.gov. Interested parties should contact Keith Ryales for any questions/comments. The projected solicitation date is June 2022.